ArticleCurrent opinion in hematology2019
The role of CXCR2 in acute inflammatory responses and its antagonists as anti-inflammatory therapeutics.
Article in Current opinion in hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 50 citations in OpenAlex.
- Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19.PLoS pathogens · 2021Trial
- Functional and Transcriptional Responses of Neutrophils from Dogs Living Under Different Housing Conditions Following In Vitro Lipopolysaccharide Stimulation.International journal of molecular sciences · 2026Article
- Article
- Neutrophils exhibit distinct migration phenotypes that are modulated by transendothelial migration.Communications biology · 2026Article
- The dual non-competitive CXCR1/2 inhibitor ladarixin impairs neutrophil extravasation without altering intravascular adhesion.Haematologica · 2026Article
- Ziyuglycoside II ameliorates chemotherapy-induced neutropenia by promoting neutrophil differentiation and functional recovery via SPI1 and C/EBPϵ transcriptional regulation.Frontiers in immunology · 2026Article
- Monocytes and neutrophils promote cardiac fibroblast pro-fibrotic phenotypes through IL-6 and MIF.Frontiers in cell and developmental biology · 2026Article
- CommensalbioRxiv : the preprint server for biology · 2025Article
- Chemokine-receptor-guided B-cell immunity in cardiovascular disease.Basic research in cardiology · 2025Review
- Bulk RNAseq Analysis of Cardiac Myosin-Specific CD4Biomedicines · 2025Article
- Neutrophil Dynamics Contribute to Disease Progression and Poor Survival in Pancreatic Cancer.Cancers · 2025Article
- Article
- Hyperlipidemia-associated specific modules and hub genes revealed by integrative methods of WGCNA and MetaDE.Frontiers in genetics · 2025Article
- The Oral Microbiome of Peri-Implant Health and Disease: A Narrative Review.Dentistry journal · 2024Review
- Single-cell multiomic analysis identifies macrophage subpopulations in promoting cardiac repair.The Journal of clinical investigation · 2024Article
- Alterations in gene expression and microbiome composition upon calcium-sensing receptor deletion in the mouse esophagus.American journal of physiology. Gastrointestinal and liver physiology · 2024Article
- Systematic assessment of chemokine ligand bias at the human chemokine receptor CXCR2 indicates G protein bias over β-arrestin recruitment and receptor internalization.Cell communication and signaling : CCS · 2024Article
- CXCR2 chemokine receptor - a master regulator in cancer and physiology.Trends in molecular medicine · 2024Review
- Development of protein-polymer conjugate nanoparticles for modulation of dendritic cell phenotype and antigen-specific CD4 T cell responses.ACS applied polymer materials · 2023Article
- Exosomal PGE2 from M2 macrophages inhibits neutrophil recruitment and NET formation through lipid mediator class switching in sepsis.Journal of biomedical science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
purpose of reviewCXCR2 is key stimulant of immune cell migration and recruitment, especially of neutrophils. Alleviating excessive neutrophil accumulation and infiltration could prevent prolonged tissue damage in inflammatory disorders. This review focuses on recent advances in our understanding of the role of CXCR2 in regulating neutrophil migration and the use of CXCR2 antagonists for therapeutic benefit in inflammatory disorders. RECENT
findingsRecent studies have provided new insights into how CXCR2 signaling regulates hematopoietic cell mobilization and function in both health and disease. We also summarize several CXCR2 regulatory mechanisms during infection and inflammation such as via Wip1, T-bet, P-selectin glycoprotein ligand-1, granulocyte-colony-stimulating factor, and microbiome. Moreover, we provide an update of studies investigating CXCR2 blockade in the laboratory and in clinical trials. SUMMARY: Neutrophil homeostasis, migration, and recruitment must be precisely regulated. The CXCR2 signaling pathway is a potential target for modifying neutrophil dynamics in inflammatory disorders. We discuss the recent clinical use of CXCR2 antagonists for controlling inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.